Mirabegron
- Generic Name
- Mirabegron
- Brand Names
- Myrbetriq, Betmiga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24N4O2S
- CAS Number
- 223673-61-8
- Unique Ingredient Identifier
- MVR3JL3B2V
- Background
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
- Indication
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04023253
- Locations
- 🇨🇳
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan
Beta 3 Agonist Treatment in Heart Failure-2
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Henning Bundgaard
- Target Recruit Count
- 56
- Registration Number
- NCT03926754
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron
- Conditions
- Interventions
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2021-06-22
- Target Recruit Count
- 20
- Registration Number
- NCT03612401
- Locations
- 🇺🇸
South Texas Veterans Health Care System, Audie L. Murphy Hospital, San Antonio, Texas, United States
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 50
- Registration Number
- NCT03600766
- Locations
- 🇪🇬
Urology and nephrology center, Mansourah, Dakahlia, Egypt
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 805
- Registration Number
- NCT03572231
- Locations
- 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷Site KR410009, Incheon, Korea, Republic of
🇰🇷Site KR410005, Kangam, Korea, Republic of
Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT03412513
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷Hallym University Medical Center, Gyeonggi-do, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Kessler Foundation
- Target Recruit Count
- 62
- Registration Number
- NCT03187795
- Locations
- 🇺🇸
Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
- Conditions
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 100
- Registration Number
- NCT03049462
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Buddhist Tzu Chi General Hospital
- Target Recruit Count
- 574
- Registration Number
- NCT03044912
- Locations
- 🇨🇳
Buddhist Tzu Chi General Hospital, Hualien, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.